Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2002
10/23/2002EP1250937A2 Controlled dissolution of active ingredients
10/23/2002EP1250936A1 Use of starch for transdermal applications
10/23/2002EP1250933A1 Vaccines including as an adjuvant high dose type I IFN
10/23/2002EP1250932A1 A stable aqua formulation of interferon, the preparation method and the uses thereof
10/23/2002EP1250927A2 Pharmaceutical composition for topical application comprising nifedipine
10/23/2002EP1250925A2 Nasal spray containing ondansetron hydrochloride
10/23/2002EP1250920A1 Unloaded ion exchange resins for the extended release of active ingredients
10/23/2002EP1250919A1 Gelling, relaxing bath compositions
10/23/2002EP1250916A1 An emulsifying agent without peg and their use for the preparation at room temperature of cosmetic, phaceutical and dermatological compositions
10/23/2002EP1250849A1 Morinda citrifolia (Noni) enhanced animal food product
10/23/2002EP1250434A2 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
10/23/2002EP1250361A2 Degradable poly(vinyl alcohol) hydrogels
10/23/2002EP1250359A1 Chitosan condensation products, their preparation and their uses
10/23/2002EP1250355A1 Chimeric prostate-homing peptides with pro-apoptotic activity
10/23/2002EP1250343A1 Azalide antibiotic compositions
10/23/2002EP1250166A1 Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
10/23/2002EP1250161A2 Polymer blends as biodegradable matrices for preparing biocomposites
10/23/2002EP1250156A1 Method for nucleic acid transfection of cells
10/23/2002EP1250154A2 G-csf conjugates
10/23/2002EP1250153A2 TREATMENT OF i C. DIFFICILE /i TOXIN B ASSOCIATED CONDITIONS
10/23/2002EP1250152A1 Hyaluronic acid in the treatment of cancer
10/23/2002EP1250151A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
10/23/2002EP1250149A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer
10/23/2002EP1250143A2 Reduction in bacterial colonization by administering bacteriophage compositions
10/23/2002EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002EP1250138A1 Fulvestrant formulation
10/23/2002EP1250134A1 Compositions for the prevention of diaper dermatitis
10/23/2002EP1250133A1 Ophthalmic anti-allergy compositions suitable for use with contact lenses
10/23/2002EP1250132A1 Ibuprofen containing active agent preparation
10/23/2002EP1250130A1 Propofol formulation with enhanced microbial inhibition
10/23/2002EP1250126A2 Transepithelial delivery of glp-1 derivatives
10/23/2002EP1250125A2 Pharmaceutical compositions comprising terbinafine
10/23/2002EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application
10/23/2002EP1250094A1 Tunable indocyanine dyes for biomedical applications
10/23/2002EP1250056A1 Composition for intestinal delivery
10/23/2002EP1250055A1 Immune modulation with death receptor-induced apoptosis
10/23/2002EP1250053A2 Method for produce sanitation using bacteriophages
10/23/2002EP1250050A2 Method and device for sanitation using bacteriophages
10/23/2002EP1250046A1 Improved topical drug delivery composition and method
10/23/2002EP1144009B1 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
10/23/2002EP1107734B1 Oral liquid mucoadhesive compositions
10/23/2002EP0994727B1 Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles
10/23/2002EP0977626B1 Composition based on alkylpolyglycosides and fatty alcohols, and uses thereof
10/23/2002EP0885014B1 Pharmaceutical compositions containing buffered ortho ester polymers
10/23/2002EP0844269B1 Block copolymer having functional groups at both ends
10/23/2002EP0822217B1 Heterotelechelic block copolymers and process for producing the same
10/23/2002EP0804241B1 Utilization of ethoxylated fatty acid esters as self-emulsifiable compounds
10/23/2002EP0775173B1 Starch-bound cellular matrix
10/23/2002CN1376166A Peptide that lower blood glucose levels
10/23/2002CN1376164A Gcsf缀合物 Gcsf conjugates
10/23/2002CN1376148A Rate-controlled particles
10/23/2002CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002CN1376074A Antibody-dye conjugates for binding to target structures of angiogenesis in order to introperatively depict tumor peripheries
10/23/2002CN1376073A Method of expressing antigen on the surface of an antigen-presenting cell by photochemical internalisation
10/23/2002CN1376071A Anti cancer agent and method of treatment of cancer
10/23/2002CN1376065A Compositions having improved stability
10/23/2002CN1376059A Hydrodynamically balancing oral drug delivery system
10/23/2002CN1376057A Anti-virus composition
10/23/2002CN1376056A Liposome-entrapped DNA oral vaccines
10/23/2002CN1376055A Aerosol ointment compositions and method of manufacture
10/23/2002CN1376054A Topcial suspension formulations containing ciprofloxacin and dexa methasone
10/23/2002CN1376043A Drug delivery of phase changing formulation
10/23/2002CN1375453A Heterogeneous silica as carrier material
10/23/2002CN1092995C Oil-in-water emulsifiers
10/23/2002CN1092990C Modulation of cell proliferation and wound healing
10/23/2002CN1092988C Thermally stabilized contrast agent
10/23/2002CN1092987C Delivery of therapeutic agents to receptors using polysaccharides
10/23/2002CN1092986C CoA oral preparation for reducing blood fat and its preparation method and application
10/23/2002CN1092960C Pharmaceutical composition comprising proteinase inhibitor and monoglyceride
10/23/2002CN1092959C Pharmaceutical composition contg. tiagabine or receptive salt and process for its preparation
10/23/2002CN1092956C Sustained release drug formulation containing a tramadol salt
10/23/2002CN1092954C Ophthalamic compositions containing cyclotextrins and quatemary ammonium compound
10/23/2002CA2383149A1 Process for partially reducing or eliminating the symptoms associated with the release of histamine in the body
10/23/2002CA2383115A1 Use of an effective amount of at least one ion chelating agent to enhance the tolerance level of sensitive or intolerant skin
10/22/2002WO2001091753A1 Active substance combination containing an opioid having a fentanyl-type structure and ketamine
10/22/2002US6469187 Contaminant reduced marine oil
10/22/2002US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
10/22/2002US6469069 Propofol composition containing sulfite
10/22/2002US6469066 Treating burns with one or more of acetic acid, vinegar and citric acid for prevention of delayed hyperalgesia
10/22/2002US6469022 By inhibition of the p-glycoprotein efflux pump, a multidrug transporter, in the intestinal mucosa; allowing intracellular accumulation of drug
10/22/2002US6468989 Gel compositions containing metronidazole
10/22/2002US6468986 Composition comprising polynucleotide and polycationic agent which exhibits net positive electrical charge at physiological ph, and is capable of mediating entry of polynucleotides into cell
10/22/2002US6468981 Compound comprising steroid moiety which binds to androgen receptor covalently linked to polycationic salt complexed with nucleic acid capable of therapeutically modifying or revealing presence of androgen receptor-containing cell
10/22/2002US6468968 Comprising a cyclosporin in a carrier medium of a fatty acid triglyceride and a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester; biavailability; side-effect reductions
10/22/2002US6468962 Nutritional intervention composition for enhancing and extending satiety
10/22/2002US6468961 Gel composition and methods
10/22/2002US6468960 Therapeutic compositions and methods for enhancing angiogenesis
10/22/2002US6468798 Liposome-nucleic acid complexes are prepared then delivered via aerosol to the lung airway; for transforming pulmonary cells and treating lung diseases
10/22/2002US6468557 Method for treating infectious viral diseases
10/22/2002US6468553 Extract containing puccoon and chinese angelica
10/22/2002US6468549 Gelling or thickening a cosmetic or dermatological composition
10/22/2002US6468548 Autoclavable pharmaceutical compositions containing a chelating agent
10/22/2002US6468532 Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
10/22/2002US6468530 Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
10/22/2002US6468527 Biological bioadhesive composition and methods of preparation and use
10/22/2002US6468526 For therapy of vaginal and gastrointestinal infections
10/22/2002US6468522 Derivatives of polymers such as polyethylene glycol containing thiol groups; disulfide linkage with thioamide modifed drug or prodrug; better oral bioavailability and tissue specific targeting
10/22/2002US6468519 Polyanhydrides with biologically active degradation products
10/22/2002US6468507 Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
10/22/2002US6468488 Mg-Al anionic clay having 3R2 stacking